Application of preoperative brain natriuretic peptide levels in clinical practice

Vascular ◽  
2013 ◽  
Vol 21 (4) ◽  
pp. 225-231 ◽  
Author(s):  
Marlin Wayne Causey ◽  
Derek P McVay ◽  
Morohunranti Oguntoye ◽  
Charles Andersen ◽  
Niten Singh
Keyword(s):  
Clinical Practice ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Multivariable Analysis ◽  
Arterial Disease ◽  
Cardiac Complications ◽  
Postoperative Risk ◽  
Receiver Operator Curve Analysis ◽  
Artery Disease ◽  
Peripheral Arterial

The purpose of the study was to determine the clinical utility and practical application of preoperative brain natriuretic peptide (BNP) levels. This is a retrospective review of operating room procedures from November 2006 to March 2009. Preoperative history and physical were reviewed and BNP laboratory levels obtained prior to all procedures and the postoperative course reviewed for incidence of 30-day cardiac complications. A receiver operator curve analysis demonstrated that a preoperative BNP threshold ≥95.5 pg/mL correctly identified 75% of patients with cardiac complications and values ≤18.5 pg/mL identified 100% of patients without adverse postoperative cardiac complications. Multivariable analysis also revealed a history of peripheral arterial disease as the most significant preoperative predictor of cardiac complications followed by BNP above the threshold (odds ratio = 3.7), hypothyroidism, coronary artery disease and prior myocardial infarction. In conclusion, preoperative BNP levels are a useful adjunct in clinical practice to help identify those patients with a high postoperative risk and those with a minimal postoperative risk.

In Hospital outcome of Prediction of Peripheral Arterial disease In Diabetic Tobacco User Patients

2018 ◽  
Vol 9 (2) ◽  
pp. 102-109
Author(s):  
Syed Dawood Md Taimur ◽  
Sahela Nasrin ◽  
M Maksumul Haq ◽  
Hemanta I Gomes ◽  
Farzana Islam
Keyword(s):  
Clinical Practice ◽  
Peripheral Artery Disease ◽  
Arterial Disease ◽  
User Group ◽  
Peripheral Artery ◽  
Tobacco User ◽  
Group I ◽  
Group Ii ◽  
Artery Disease ◽  
Peripheral Arterial

Background: Peripheral artery disease (PAD) is a distinct atherosclerotic disorder marked by stenosis of the arteries common in tobacco users. Here we investigate prediction of unknown peripheral arterial disease (PAD) amongst patients with diabetic tobacco user and diabetic without tobacco user.Methodology: This prospective observational study was conducted in the Department of Cardiology, Ibrahim Cardiac Hospital and Research Institute, Dhaka, Bangladesh. A total of 60 patients were enrolled in this study who were presented with chest pain associated with lower limb claudication. They were diabetic population, constituted tobacco user in group-I and without tobacco user in group-II.Results: Hypertension was the leading risk factor in both groups (76.7% vs. 80%). 80% of patients of group I and 46.7% of patients of group II had mild form of ABI value. 3.3% of patient of group II had severe form of ABI value. There was no statistical significant difference between two group of patients (p=0.053). 93.3% patients of group I and 96.7% patients of group II had coronary artery disease. Twenty three patients of tobacco user group (n=30) had peripheral artery disease, whereas ten patients of without tobacco user group (n=30) had peripheral artery disease which was statistically significant (p=0.003). Three quarters (76.7%) of group I developed PVD as compared to 33.3% of group II. The risk of developing PVD in diabetic smokers was observed to be more than 6 fold (95% CI: 2.109-20.479) higher than that in non tobacco user were diabetics. 16.7% patients of group I atherosclerosis in femoral artery and the value is 10% in case of group-II, which is statistically in significant(p=0.433).Conclusion: The awareness and implementation of ABI in general clinical practice is poor. A simple, inexpensive test like ABI can improve the diagnosis of PAD in clinical practice and thus help in preventing CAD and consequent death by a range of medical therapies.Anwer Khan Modern Medical College Journal Vol. 9, No. 2: Jul 2018, P 102-109

Ischemia-modified albumin and NT-prohormone-brain natriuretic peptide in peripheral arterial disease

2006 ◽  
Vol 44 (2) ◽  
Author(s):  
Martina Montagnana ◽  
Giuseppe Lippi ◽  
Cristiano Fava ◽  
Pietro Minuz ◽  
Clara Lechi Santonastaso ◽  
...  
Keyword(s):  
Heart Failure ◽  
Peripheral Arterial Disease ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Troponin T ◽  
Myocardial Dysfunction ◽  
Arterial Disease ◽  
Ischemia Modified Albumin ◽  
Increased Risk ◽  
Peripheral Arterial

AbstractCardiovascular disease is the leading cause of mortality and morbidity in Western countries. Despite its remarkable medical and social consequences, the prevalence of peripheral arterial disease (PAD) is often underestimated among atherosclerotic disorders. So far, little is known about the behavior of traditional and emerging markers of ischemic heart disease that should allow the reliable identification of PAD patients at increased risk of developing myocardial ischemia and heart failure or dysfunction. To investigate this topic, we measured cardiac troponin T (cTnT), ischemia-modified albumin (IMA) and NT-prohormone-brain natriuretic peptide (NT-proBNP)in 35 consecutive patients with clinically ascertained PAD (stage 2–4, according to Lériche-Fontaine) asymptomatic for chest pain and current heart failure, and 20 controls displaying moderate to high cardiovascular risk factors (hypertension, diabetes, hyperlipidemia), but with no clinical evidence of PAD. Although the concentrations of cTnT and IMA were not statistically increased in PAD patients, NT-pro-BNP values were substantially higher in PAD patients than in controls (62.6 vs. 7.4pmol/L, p<0.0001). Thepercentage of subjects displaying values exceeding the specific NT-proBNP diagnostic threshold (>14.8pmol/L) was also significantly different between PAD patients and controls (74% vs. 10%, p<0.001). After excluding PAD patients exceeding the 0.01ng/mL cTnT cutoff value indicative of current ischemic cardiac involvement, the median concentration of NT-proBNP remained statistically increased (28.0 vs. 5.8pmol/L, p<0.0001). Taken together, these results indicate that NT-proBNP, but not IMA, is substantially increased in PAD patients. This finding suggests that such patients, even though asymptomatic, might develop myocardial dysfunction, and thus warrant further investigation.

Ankle Brachial Pressure Index and compression application: Review summary

2019 ◽  
Vol 27 (2) ◽  
pp. 74-77
Author(s):  
Victoria Team ◽  
Georgina Gethin ◽  
John D Ivory ◽  
Kimberley Crawford ◽  
Ayoub Bouguettaya ◽  
...  
Keyword(s):  
Content Analysis ◽  
Clinical Practice ◽  
Venous Insufficiency ◽  
Arterial Disease ◽  
Leg Ulcers ◽  
Current Clinical Practice ◽  
Ankle Brachial Pressure Index ◽  
Arterial Circulation ◽  
Pressure Index ◽  
Peripheral Arterial

Venous leg ulcers (VLUs) are a significant complication amongst persons with chronic venous insufficiency (CVI) that frequently follow a cycle of healing and recurrence. Current clinical practice guidelines (CPGs) recommend applying below knee compression to improve VLU healing. Compression could be applied if the Ankle Brachial Pressure Index (ABPI) rules out significant arterial disease, as sufficient peripheral arterial circulation is necessary to ensure safe compression use. We conducted a content analysis of 13 global CPGs on the accuracy of recommendations related to ABPI and compression application. Eight CPGs indicated that compression is recommended when the ABPI is between 0.8 and 1.2 mmHg. However, this review found there is disagreement between 13 global VLU CPGs, with a lack of clarity on whether or not compression is indicated for patients with ABPIs between 0.6 and 0.8 mmHg. Some CPGs recommend reduced compression for treatment of VLUs, while others do not recommend any type of compression at all. This has implications for when it is safe to apply compression, and the inconsistency in evidence indicates that specialist advice may be required at levels beyond the ABPI “safe” range listed above.

scholarly journals N-Terminal Pro-Brain Natriuretic Peptide and Right Ventricular Diameter Are Related to Aspirin Resistance in Coronary Artery Disease Patients

Medicina ◽  
2021 ◽  
Vol 57 (7) ◽  
pp. 706
Author(s):  
Kamila Marika Cygulska ◽  
Łukasz Figiel ◽  
Dariusz Sławek ◽  
Małgorzata Wraga ◽  
Marek Dąbrowa ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Brain Natriuretic Peptide ◽  
Right Ventricular ◽  
Left Ventricular Mass ◽  
Natriuretic Peptide ◽  
Hemoglobin Concentration ◽  
Left Ventricular ◽  
Ventricular Mass ◽  
Artery Disease

Background and Objectives: Resistance to ASA (ASAres) is a multifactorial phenomenon defined as insufficient reduction of platelet reactivity through incomplete inhibition of thromboxane A2 synthesis. The aim is to reassess the prevalence and predictors of ASAres in a contemporary cohort of coronary artery disease (CAD) patients (pts) on stable therapy with ASA, 75 mg o.d. Materials and Methods: We studied 205 patients with stable CAD treated with daily dose of 75 mg ASA for a minimum of one month. ASAres was defined as ARU (aspirin reaction units) ≥550 using the point-of-care VerifyNow Aspirin test. Results: ASAres was detected in 11.7% of patients. Modest but significant correlations were detected between ARU and concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP) (r = 0.144; p = 0.04), body weight, body mass index, red blood cell distribution width, left ventricular mass, and septal end-systolic thickness, with trends for left ventricular mass index and prothrombin time. In multivariate regression analysis, log(NT-proBNP) was identified as the only independent predictor of ARU—partial r = 0.15, p = 0.03. Median concentrations of NT-proBNP were significantly higher in ASAres patients (median value 311.4 vs. 646.3 pg/mL; p = 0.046) and right ventricular diameter was larger, whereas mean corpuscular hemoglobin concentration was lower as compared to patients with adequate response to ASA. Conclusions: ASAres has significant prevalence in this contemporary CAD cohort and NT-proBNP has been identified as the independent correlate of on-treatment ARU, representing a predictor for ASAres, along with right ventricular enlargement and lower hemoglobin concentration in erythrocytes.

Sign in / Sign up

Export Citation Format

Share Document